SARMs-onderzoek: huidige stand en toekomstige richtingen

Selective Androgen Receptor Modulators (SARMs) represent a revolutionary class of compounds in pharmaceutical research. Unlike traditional anabolic agents, SARMs are designed to selectively activate androgen receptors in specific tissues while minimizing effects on others.

Understanding SARMs

SARMs are non-steroidal compounds that bind to androgen receptors with high affinity and selectivity. This tissue-selective mechanism of action distinguishes them from traditional androgens and makes them valuable tools for understanding receptor biology.

2024-2025 Research Status

Important Note: SARMs remain unapproved for human use despite ongoing research. Clinical trials have shown anabolic effects like increased lean body mass but have not demonstrated superior tissue selectivity over traditional androgens or significant clinical benefits beyond body composition changes.

Key Research Findings

Tissue Selectivity Under Scrutiny: Recent reviews critically appraise SARMs' claimed muscle-specific effects. Scientists now attribute observed selectivity to metabolic differences (such as lack of 5α-reductase amplification) rather than unique molecular mechanisms. No head-to-head trials have confirmed advantages over conventional androgens.

Anabolic Efficacy: Short-term trials report lean body mass gains comparable to testosterone. For example, GSK2881078 matched 125 mg/week testosterone over 20 weeks in just 8 weeks of treatment.

Molecular Insights: Computational studies on compounds like YK11 show strong androgen receptor binding and conformational stability, suggesting potential for optimized profiles in androgen-related research.

SARMs Under Investigation

Enobosarm (Ostarine/MK-2866): The most extensively studied SARM, targeting muscle wasting and fat loss conditions. Research shows improved lean body mass but limited effects on quality of life measures.

Ligandrol (LGD-4033): Demonstrated increases in lean body mass in clinical trials, with dose-dependent effects on hormone suppression.

RAD-140 (Vosilasarm): High anabolic potency in preclinical models with investigation into safety profiles ongoing.

GSK2881078: Phase 2 trials showed high anabolic potency with gender-variable sensitivity.

Safety Considerations and Side Effects

SARMs exhibit relative selectivity but still activate androgen receptors in skin, hair, liver, and heart. Reported issues from research include:

• Liver enzyme elevations
• Testosterone suppression
• Effects on bone remodeling
• Potential cardiovascular impacts

Social media analyses highlight prevalence of adverse events among non-supervised users, emphasizing the importance of controlled research settings.

Regulatory Status

As of 2025, no SARMs have received FDA approval. They are:

• Banned by WADA (World Anti-Doping Agency)
• Not approved for human therapeutic use
• Available only for research purposes
• Subject to strict regulatory oversight

Research Applications

Current scientific applications focus on:

• Understanding androgen receptor biology
• Investigating tissue-selective mechanisms
• Developing models for muscle wasting conditions
• Studying bone metabolism and osteoporosis

The scientific community emphasizes that SARMs represent important research tools for understanding androgen signaling, but clinical translation requires further rigorous investigation.